UY39526A - Inhibidores de kras g12d - Google Patents

Inhibidores de kras g12d

Info

Publication number
UY39526A
UY39526A UY0001039526A UY39526A UY39526A UY 39526 A UY39526 A UY 39526A UY 0001039526 A UY0001039526 A UY 0001039526A UY 39526 A UY39526 A UY 39526A UY 39526 A UY39526 A UY 39526A
Authority
UY
Uruguay
Prior art keywords
inhibitors
kras
prodrug
formula
composition containing
Prior art date
Application number
UY0001039526A
Other languages
English (en)
Inventor
Hao Zhang
Huifeng Han
Panliang Gao
Wenlong Zhang
Cunbo Ma
Peng Wang
Dan Liu
Wei Long
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of UY39526A publication Critical patent/UY39526A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con inhibidores de KRAS G12D de la fórmula (I), una composición que contiene los inhibidores, una prodroga de los mismos, un compuesto PROTAC de los mismos y el uso de los mismos.
UY0001039526A 2020-11-20 2021-11-19 Inhibidores de kras g12d UY39526A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2020130351 2020-11-20
CN2021091540 2021-04-30
CN2021092466 2021-05-08
CN2021099242 2021-06-09
CN2021100130 2021-06-15
CN2021102172 2021-06-24
CN2021122046 2021-09-30

Publications (1)

Publication Number Publication Date
UY39526A true UY39526A (es) 2022-06-30

Family

ID=81708410

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039526A UY39526A (es) 2020-11-20 2021-11-19 Inhibidores de kras g12d

Country Status (5)

Country Link
US (1) US20240025918A1 (es)
CN (1) CN116490508A (es)
TW (1) TW202229285A (es)
UY (1) UY39526A (es)
WO (1) WO2022105857A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022194066A1 (zh) * 2021-03-15 2022-09-22 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
CN117222650A (zh) * 2021-04-30 2023-12-12 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物，其制法与医药上的用途
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN116332959A (zh) * 2021-12-24 2023-06-27 苏州泽璟生物制药股份有限公司 Krasg12d蛋白水解调节剂及其制备方法和应用
WO2023138524A1 (zh) * 2022-01-24 2023-07-27 贝达药业股份有限公司 Kras g12d降解剂及其在医药上的应用
WO2023154766A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2024040080A1 (en) * 2022-08-19 2024-02-22 Erasca, Inc. Kras inhibitor conjugates
WO2024054926A1 (en) * 2022-09-07 2024-03-14 Bristol-Myers Squibb Company Kras g12d inhibitors
WO2024050742A1 (en) * 2022-09-08 2024-03-14 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway
WO2024054647A1 (en) * 2022-09-09 2024-03-14 Ranok Therapeutics (Hangzhou) Co. Ltd. 4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-naphthalene-pyrido[4,3-d]pyrimidine derivatives as inhibitors of the kras(g12d) mutant oncoproteine for the treatment of cancer
CN115894198B (zh) * 2022-11-04 2024-05-17 浙江永太科技股份有限公司 Qulipta的关键中间体1-(2,3,6-三氟苯基)丙烷-2-酮的制备方法
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745385B2 (en) * 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
US11236068B2 (en) * 2018-11-09 2022-02-01 Genentech, Inc. Fused ring compounds
TW202110837A (zh) * 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
WO2022105857A1 (en) 2022-05-27
US20240025918A1 (en) 2024-01-25
TW202229285A (zh) 2022-08-01
CN116490508A (zh) 2023-07-25

Similar Documents

Publication Publication Date Title
UY39526A (es) Inhibidores de kras g12d
CL2022000447A1 (es) Inhibidores de kras g12d
CO2021016018A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
CL2021001461A1 (es) Moduladores de trex1
AR088673A1 (es) Formulaciones de peliculas para los dientes
CL2021000031A1 (es) Compuestos heterocíclicos antihelmínticos
CO2023016204A2 (es) Inhibidores de nlrp3
CR20230115A (es) Compuestos heterocíclicos
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
CL2020002216A1 (es) Uso de compuestos de alcoxi pirazol funcionalizados con n como inhibidores de la nitrificación
CL2023000313A1 (es) Forma sólida de un compuesto
MX2020009022A (es) Uso de alcoxipirazoles como inhibidores de la nitrificacion.
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
CO2023015732A2 (es) Moduladores de trex1
ECSP23089582A (es) Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3
CL2020003214A1 (es) Nuevos derivados de isoxazolil éter como pam de gaba a alfa5
AR124109A1 (es) Inhibidores de kras g12d
CO2022007621A2 (es) Nuevos inhibidores de braf como rompedores de la paradoja
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1